Christopher S. Seet, MD, PhD
- Hematologic Malignancy|
- Hematology Oncology
About
Dr. Christopher Seet is a hematologist and oncologist subspecializing in the treatment of hematologic malignancies, including hematopoietic stem cell transplantation, cellular therapy, and clinical trials of novel therapeutics. Dr. Seet received his undergraduate degree in Biological Science at the University of Chicago; medical degree at the University of Sydney, Australia; and PhD in Cellular and Molecular Pathology at UCLA. Dr. Seet completed internship and residency in Internal Medicine at Loyola University Medical Center in Chicago, and Hematology/Oncology fellowship at UCLA. Dr. Seet has an active basic science and translational research program in developmental immunology and cellular immunotherapy. His research focuses on human T cell and dendritic cell tumor immunology, and the development of engineered stem cell-based approaches to cancer immunotherapy.
Dr. Seet is a Broad Stem Cell Research Center Clinical Fellow, recipient of a UCLA KL2 Translational Science Award, and a previous UCLA STAR program fellow. He is a member of the American Society of Hematology and American Society of Clinical Oncology.
Specialties:
- Acute myeloid leukemia
- Acute lymphocytic leukemia
- Aplastic anemia and bone marrow failure
- Bone marrow transplantation
- Cellular therapy and immunotherapy
- Chronic myelogenous leukemia
- Myelodysplastic syndrome
- Myeloproliferative disorders
- Multiple myeloma
- Investigational agents
Languages
Education
Medical Board Certifications
Fellowship
Residency
Internship
Degrees
Recognitions
- NIH/UCLA CTSI KL2 Translational Science Award, 2017, 2018
- Broad Stem Cell Research Center at UCLA Clinical Fellow, 2016, 2017, 2018
- 1st Place, Department of Medicine Poster Competition, David Geffen School of Medicine at UCLA, 2017
- See More
Locations
Hospital Affiliations
Ronald Reagan UCLA Medical Center
UCLA Santa Monica Medical Center
Medical Services
Research
Publications
- Seet, C.S., He C, Bethune M.T., Li, S, Chick, B., Gschweng, E.H., Zhu, Y., Kim K., Kohn, D.B., Baltimore, D., *Crooks GM, *Montel-Hagen A. (2017) Generation of mature T cells from human hematopoietic stem-progenitor cells in artificial thymic organoids. Nature Methods, 2017 Apr 3.
- Seet C.S., Li, S., Chick, B., Casero, D., Gschweng, E.H., Zhu, Y., Miao, R., Montel-Hagen, A., Kohn, D.B., Sehl, M., Crooks, G.M., Notch Signaling Promotes the Differentiation of Human CLEC9A+ Dendritic Cells from Hematopoietic Stem and Progenitor Cells, Oral Presentation, American Society of Hematology (ASH) 59th Annual Meeting, Atlanta, GA, Dec. 11, 2017
- Montel-Hagen, A.*, Seet C.S.* (*co-first authors), Li, S., Chick, B., Chang, P., Zhu, Y., He, C., Lopez, S., Crooks, G.M., In Vitro Generation of Human Pluripotent Stem Cell-Derived T Cells for Immunotherapy, Oral Presentation, American Society of Hematology (ASH) 59th Annual Meeting, Atlanta, GA, Dec. 11, 2017
- Casero D., Sandoval S., Seet C.S., Scholes J., Zhu Y., Ha V., Parekh C, Crooks G.M. (2015) Long non-coding RNA profiling of human lymphoid progenitor cells reveals transcriptional divergence of B cell and T cell lineages. Nature Immunology, Dec;16(12):1282-91
- Seet C.S., Crooks G.M., (2025), Chapter 74: Lymphopoiesis, Williams Hematology, 9th Edition, Kaushansky K. et al. (Editor), McGraw-Hill Education
- Berent-Maoz B., Montecino-Rodriguez E., Fice M., Casero D, Seet C.S., Crooks G. M., Lowry W., Dorshkind K. (2015) The Expansion of Thymopoiesis in Neonatal Mice is Dependent on Expression of High mobility group A 2 protein (Hmga2), PLOS One, May 1;10(5):e0125414.
- Kohn L. A., Seet C.S., Scholes J., Codrea F., Chan R., Zaidi-Merchant S., Zhu Y. De Oliveira S., Kapoor N., Shah A., Abdel-Azim H., Kohn D.B., Crooks G.M. (2014) Human lymphoid development in the absence of common y-chain receptor signaling, J Immunol. Jun 1;192(11):5050-8.
- Zhang J.*, Seet C.S.* (*co-first authors), Sun C., Li J., You D., Volk A., Breslin P., Li X., Wei W., Qian Z., Zeleznik-Le, N.J., Zhang Z., Zhang J. (2013) p27kip1 maintain a subset of leukemia stem cells in the quiescent state in murine MLL-leukemia. Molecular Oncology, Dec;7(6):1069-82.
In the News
Artificial organ may help patients form the cancer-fighting cells they need - digitaltrends.com
Artificial thymus developed at UCLA can produce cancer-fighting T cells from blood stem cells - UCLA Newsroom
Note: News links may expire without notice.
Insurance
- Aetna
- Anthem Blue Cross
- Blue Shield of California
- Centivo
- Cigna
- First Health
- Health Net of California
- Interplan (part of HealthSmart)
- L.A. Care
- MultiPlan
- UFCM Health System
- Prime Health Services
- Private Healthcare Systems (PHCS)
- TRICARE
- UnitedHealthcare
The list of health care plans above may not be comprehensive and could change.
Please contact your benefits coordinator or health insurance company directly to verify coverage.
Visit our health insurance information page for more details.
Recognitions
- NIH/UCLA CTSI KL2 Translational Science Award, 2017, 2018
- Broad Stem Cell Research Center at UCLA Clinical Fellow, 2016, 2017, 2018
- 1st Place, Department of Medicine Poster Competition, David Geffen School of Medicine at UCLA, 2017
- UCLA CTSI Core Voucher Award, 2017
- Career Development Award, Tower Cancer Research Foundation, 2015
- Research Innovator Award, Department of Medicine, David Geffen School of Medicine at UCLA, 2015
- Young Investigator Award at ImmunologyLA, American Association of Immunologists, 2015
- NIH T32 Hematology Training Grant, 2013-2016
- Fellow Teaching Award Nominee, Department of Medicine, David Geffen School of Medicine at UCLA, 2012